Bellerophon Therapeutics (Bellerophon Therapeutics) Operating Cash Flow per Share : $-1.07 (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Operating Cash Flow per Share?

Bellerophon Therapeutics's operating cash flow per share for the three months ended in Sep. 2023 was $-0.52. Bellerophon Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.07.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 13.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 18.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 34.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Bellerophon Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

BLPH' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -10.3 Med: 30.85 Max: 60.2
Current: 13.5

During the past 11 years, Bellerophon Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 60.20% per year. The lowest was -10.30% per year. And the median was 30.85% per year.

BLPH's 3-Year OCF Growth Rate is ranked better than
59.47% of 1241 companies
in the Biotechnology industry
Industry Median: 3.7 vs BLPH: 13.50

Bellerophon Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Bellerophon Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Operating Cash Flow per Share Chart

Bellerophon Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

Get a 7-Day Free Trial

-3.57

-2.87

-2.55

-2.40

-1.86

Bellerophon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.53	-0.46	0.31	-0.40	-0.52

Competitive Comparison of Bellerophon Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Bellerophon Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bellerophon Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellerophon Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Bellerophon Therapeutics's Price-to-Operating-Cash-Flow falls into.

Bellerophon Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Bellerophon Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	-17.77	/	9.551
	=	-1.86

Bellerophon Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Sep. 2023 )	=	Cash Flow from Operations (Q: Sep. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2023 )
	=	-6.332	/	12.233
	=	-0.52

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.07

Bellerophon Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059

Website

https://www.bellerophon.com

Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.

Executives

Puissance Life Science Opportunities Fund Vi	10 percent owner	950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin	director	53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang	director	C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder	director	C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc	10 percent owner	950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah	officer: VP of Business Operations	C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker	officer: See Remarks	53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes	officer: See Remarks	PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim	officer: VP Reg. Affairs & Quality	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona	officer: Controller, (PFO & PAO)	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky	10 percent owner	C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c.	10 percent owner	1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc	10 percent owner	787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019